Novartis announced today that Cosentyx® (secukinumab) met the primary endpoints in two new clinical studies, showing superior efficacy compared to placebo in patients with psoriasis of the palms, soles of

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

Existing Users Log In
   
Forgot password? Click here to reset
New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field